FINPROM Findings
2“ImmuPharma's Tim McCarthy, CEO, Dr Sébastien Goudreau, CSO, and Dr Tim Franklin, COO, will provide a live presentation ... The live presentation, via the 'Investor Meet Company' platform, will be held on Friday 20 March 2026 @ 12:00 (GMT). ... No new material will be shared at this presentation.”
Live CEO/CSO/COO presentation DURING the WRAP offer period (launched 17 Mar, presentation 20 Mar). 'No new material will be shared' is positive compliance language — but an interactive Q&A platform during an active retail raise still presents selective-disclosure risk and the 'no new material' assertion is self-certified.
“P140 Update - remains on track for licensing deal in 2026”
The IMC follow-up RNS pre-advertises a specific forward-looking claim — a named licensing deal anticipated in 2026 — alongside the WRAP offer. Standard FSMA forward-looking caveat appears in the Important Notices but the claim itself is prominent and specific.
RNS Announcements
8Result of General Meeting and TVR
the Company's issued ordinary share capital will comprise 623,911,379 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. This figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. All New Ordinary Shares have been issued free of all liens, charges and encumbrances and will, from Admission, rank pari passu in all respe…
Result of WRAP Retail Offer and TVR
THIS ANNOUNCEMENT. THIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 ("FSMA") AND HAS BEEN APPROVED BY WINTERFLOOD SECURITIES LIMITED WHICH IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY (FRN 141455). 23 March 2026 ImmuPharma PLC (" ImmuPharma " or the " Company ") Result of WRAP Retail Offer and TVR ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, further to its Fundraising announcement published on 17 March 2026 at 7:00 a.m. (the "…
‘Investor Meet Company’ presentation on 20 March
the Company's announcement, released on Tuesday 17 March 2026, titled: P140 Update - remains on track for licensing deal in 2026 Accelerated Development of Kapiglucagon for Type 1 Diabetes Subscription & WRAP Retail Offer to raise up to £7.5 million https://www.immupharma.co.uk/investors/regulatory-news/ The live presentation, via the 'Investor Meet Company' platform, will be held on Friday 20 March 2026 @ 12:00 (GMT). The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard until 19 M…
WRAP Retail Offer for up to £1.5 million
THIS ANNOUNCEMENT. THIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 ("FSMA") AND HAS BEEN APPROVED BY WINTERFLOOD SECURITIES LIMITED WHICH IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY (FRN 141455). 17 March 2026 ImmuPharma PLC (" ImmuPharma " or the " Company ") WRAP Retail Offer for up to £1.5 million ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce a retail offer via the Winterflood Retail Access Platform …
Incanthera - Comm'l Skincare Deal/£1M Fundraise
The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. For additional information about ImmuPharma please visit www.immupharma.co.uk ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895. About Incanthera plc Incanthera is a specialist company focused on in…
Result of Retail Offer and Director Shareholding
THIS ANNOUNCEMENT. 7 September 2023 ImmuPharma Plc (" ImmuPharma " or the " Company ") Result of Retail Offer and Director Shareholding ImmuPharma Plc is pleased to announce that further to the Company's announcement at 7:02 a.m. on 31 August 2023, the Company has conditionally raised gross proceeds of £130,683 through the issue of 6,534,150 New Ordinary Shares at a price of 2 pence to existing retail investors of the Company, via the Winterflood Retail Access Platform ("WRAP"), in addition to the £1.35 million raised in the Subscription and Direct Subscription. …
Subscription to raise £1.35m; Sharing Agr, RPT
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW C…
WRAP Retail Offer for up to £0.5m
THIS ANNOUNCEMENT. THE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE WRAP RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF IMMUPHARMA PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY WITH SUCH PERSONS. THIS ANNOUNCEMENT IS FOR I…
Board of Directors
23| Name | Role | Appointed | Status |
|---|---|---|---|
| Ashley Louise Clarke | Chief Financial Officer & Company Secretary | 2024-12-04 | active |
| Dr Laurence Robert Reilly | Non-Executive Director | 2023-08-11 | active |
| Ketan Ratna Patel | Independent Non-Executive Director | 2025-10-12 | active |
| Lisa Baderoon | Non-Executive Director | 2021-07-29 | active |
| Sebastien Goudreau | Non-Executive Director | 2023-08-11 | active |
| Timothy Gary Franklin | Executive Director | 2021-07-16 | active |
| Timothy Paul McCarthy | Executive Director | 2015-09-30 | active |
| Tracy Weimar | secretary | 2007-04-26 | active |
| Anthony Michael Johnson | director | 2006-02-15 | active |
| Dimitri Dimitriou | Chief Executive Officer | 2006-02-15 | active |
| Douglas Gordon James Paterson | director | 2006-02-15 | active |
| Sanjeev Pandya | Senior independent NED | 2021-07-29 | active |
| John Richard Wollenberg | director | 2000-02-21 | active |
| Dr Stephane Mery | director | 2015-04-30 | active |
| Dr Robert Henri Zimmer | director | 2006-02-15 | active |
| Dr Ajay Agrawal | director | 2007-04-26 | active |
| Dr Franco Di Muzio | director | 2007-02-07 | active |
| Ian Tewson Reynolds | director | 2003-10-07 | active |
| Derek Maurice Joseph | director | 2003-10-07 | active |
| Ewa Dagmara Flynn | secretary | 2021-01-15 | active |
| Patrick Hugh Walker Taylor | director | 2006-02-15 | active |
| Anthony Jonathan Shakesby | director | 2000-02-21 | active |
| Richard Leonard Warr | director | 2006-02-15 | active |